Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur Eiji KIRINO |
Documents disponibles écrits par cet auteur (1)
Faire une suggestion Affiner la recherche
Aripiprazole in patients with autistic spectrum disorders: a review and case reports / Eiji KIRINO in Autism - Open Access, 2-S ([01/12/2012])
[article]
Titre : Aripiprazole in patients with autistic spectrum disorders: a review and case reports Type de document : Texte imprimé et/ou numérique Auteurs : Eiji KIRINO, Auteur Article en page(s) : 10 p. Langues : Anglais (eng) Mots-clés : Aripiprazole Autistic spectrum disorder Pervasive developmental disorders Asperger’s disorder Index. décimale : PER Périodiques Résumé : Background: Although a significant amount of literature regarding use of aripiprazole (APZ) in autistic spectrum disorders (ASDs) has benne published, APZ is not approved for use in autism or ASDs in countries other than the United States. Even in the United States, approved use of APZ is limited to the patients with autism in children and adolescents. This review and case reports focus on the available evidence and clinical experience regarding the use of APZ in patients with ASDs including adults Methods: A literature review was conducted, using the PubMed search term ‘aripiprazole’ and(‘autistic spectrum disorder’, ‘pervasive developmental disorders’ or ‘Asperger’s disorder’).Results: In previous reports, APZ can target symptoms such as anxiety, depression, aggression, and irritability. Compared with other antipsychotics, APZ also causes fewer adverse events that can lead to drug discontinuation. The case reports supported the literature review: APZ has moderate sedative, antidepressant, and antianxiety effects, when used to treat ASDs. None of the patients experienced adverse reactions (e.g., extrapyramidal symptoms, weight gain, and sedation).Conclusion: APZ reduces aggression in ASDs and improves qualitative deficits in interpersonal interactions and motivation. APZ also causes fewer adverse events. APZ may be associated with favorable treatment compliance, and may improve treatment of ASDs. En ligne : https://dx.doi.org/10.4172/2165-7890.S1-004 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=409
in Autism - Open Access > 2-S [01/12/2012] . - 10 p.[article] Aripiprazole in patients with autistic spectrum disorders: a review and case reports [Texte imprimé et/ou numérique] / Eiji KIRINO, Auteur . - 10 p.
Langues : Anglais (eng)
in Autism - Open Access > 2-S [01/12/2012] . - 10 p.
Mots-clés : Aripiprazole Autistic spectrum disorder Pervasive developmental disorders Asperger’s disorder Index. décimale : PER Périodiques Résumé : Background: Although a significant amount of literature regarding use of aripiprazole (APZ) in autistic spectrum disorders (ASDs) has benne published, APZ is not approved for use in autism or ASDs in countries other than the United States. Even in the United States, approved use of APZ is limited to the patients with autism in children and adolescents. This review and case reports focus on the available evidence and clinical experience regarding the use of APZ in patients with ASDs including adults Methods: A literature review was conducted, using the PubMed search term ‘aripiprazole’ and(‘autistic spectrum disorder’, ‘pervasive developmental disorders’ or ‘Asperger’s disorder’).Results: In previous reports, APZ can target symptoms such as anxiety, depression, aggression, and irritability. Compared with other antipsychotics, APZ also causes fewer adverse events that can lead to drug discontinuation. The case reports supported the literature review: APZ has moderate sedative, antidepressant, and antianxiety effects, when used to treat ASDs. None of the patients experienced adverse reactions (e.g., extrapyramidal symptoms, weight gain, and sedation).Conclusion: APZ reduces aggression in ASDs and improves qualitative deficits in interpersonal interactions and motivation. APZ also causes fewer adverse events. APZ may be associated with favorable treatment compliance, and may improve treatment of ASDs. En ligne : https://dx.doi.org/10.4172/2165-7890.S1-004 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=409